Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lifecore BiomedicalLFCR -3.07%57 EV-to-OCF is 72.87 as of Aug. 14, 2026, which is 370% above its 10-year median of 15.50. GuruFocus rates LFCR with a GF Score™ of 57/100 and a GF Value™ of $4.86 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Lifecore Biomedical ranks worse than 91.35% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Lifecore Biomedical's Enterprise Value is $311.39 Mil.
Lifecore Biomedical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $4.27 Mil. Therefore, Lifecore Biomedical's EV-to-OCF for today is 72.87.
The historical rank and industry rank for Lifecore Biomedical's EV-to-OCF or its related term are showing as below:
LFCR'
s EV-to-OCF Range Over the Past 10 Years
Min: -2077.05 Med: 15.5 Max: 1734.54
Current: 72.87
During the past 13 years, the highest EV-to-OCF of Lifecore Biomedical was 1734.54. The lowest was -2077.05. And the median was 15.50.
LFCR's EV-to-OCF is ranked worse than 91.35% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.045
vs LFCR: 72.87
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lifecore Biomedical's PE Ratio (TTM) for today is calculated as:
Lifecore Biomedical's share price for today is $4.585.
Lifecore Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.910.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Lifecore Biomedical EV-to-OCF Related Terms
Lifecore Biomedical EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Lifecore Biomedical's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lifecore Biomedical EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Lifecore Biomedical's EV-to-OCF falls into.
Lifecore Biomedical's current Enterprise Value is $311.39 Mil.
Lifecore Biomedical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lifecore Biomedical (LFCR) has a EV-to-OCF of 72.87 as of Aug. 14, 2026. This is 370% above median its historical median of 15.50. According to the industry distribution chart, Lifecore Biomedical ranks #919 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 91.4%.
Is Lifecore Biomedical's EV-to-OCF too high?
Lifecore Biomedical's current EV-to-OCF of 72.87 is 370% above median its 10-year median of 15.50. The Drug Manufacturers industry median EV-to-OCF is 11.05. Lifecore Biomedical's value of 72.87 is 559.8% above this industry median. Based on the distribution chart, Lifecore Biomedical ranks #919 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Lifecore Biomedical has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's EV-to-OCF compare to DERM and ADCT?
According to the Drug Manufacturers industry distribution chart, Lifecore Biomedical ranks #919 out of 1006 companies for EV-to-OCF. This places Lifecore Biomedical in the lower half of its industry. The industry median EV-to-OCF is 11.05. Lifecore Biomedical's value of 72.87 is 559.8% above this benchmark. While the company's 10-year median is 15.50 vs. the industry median of 11.05, Lifecore Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.05, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lifecore Biomedical's current EV-to-OCF of 72.87 is 559.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lifecore Biomedical's current EV-to-OCF is 72.87, which is 370% above median its own 10-year median of 15.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Fairly Valued. The stock's GF Value™ is $4.86, compared to a current price of $4.59 — trading 5.7% below its estimated fair value. The current EV-to-OCF is 72.87, which is 370% above median its 10-year median of 15.50 and 559.8% above the Drug Manufacturers industry median of 11.05. Lifecore Biomedical's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current EV-to-OCF is 72.87 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lifecore Biomedical (LFCR) Overvalued in 2026?
Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued.
The current stock price of $4.59 is trading 5.7% below its estimated GF Value™ of $4.86.
GuruFocus considers Lifecore Biomedical to be Fairly Valued.
Key valuation signals for LFCR:
EV-to-OCF: 72.87 (370% above median its 10-year median of 15.50)
GF Value™: $4.86 vs. price of $4.59 (5.7% below fair value)
Industry Position: 559.8% above the Drug Manufacturers median (#919 of 1006)
No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
57GF Score
Get the complete analysis for LFCR
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFCR has been successfully added to your 
